D
David M. Hwang
Researcher at Sunnybrook Health Sciences Centre
Publications - 184
Citations - 9146
David M. Hwang is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Lung transplantation & Lung. The author has an hindex of 48, co-authored 179 publications receiving 7241 citations. Previous affiliations of David M. Hwang include Toronto General Hospital & University Health Network.
Papers
More filters
Journal ArticleDOI
A Genome-Based Resource for Molecular Cardiovascular Medicine Toward a Compendium of Cardiovascular Genes
David M. Hwang,Adam A. Dempsey,Ruoxiang Wang,Mojgan Rezvani,J. David Barrans,MHSc,Ken-Shwo Dai,Hui-Yuan Wang,Hong Ma,Eva Cukerman,Yu-Qing Liu,Jian-Ren Gu,Jing-Hui Zhang,Stephen Kwok-Wing Tsui,Mary M.Y. Waye,Kwok-Pui Fung,Cheuk Yu Lee,Choong-Chin Liew +17 more
TL;DR: These data represent the most extensive compilation of cardiovascular gene expression information to date and represent a first-generation genome-based resource for molecular cardiovascular medicine.
Journal ArticleDOI
A986S polymorphism of the calcium-sensing receptor and circulating calcium concentrations.
David E. C. Cole,Vanya Peltekova,Laurence A. Rubin,Gillian A. Hawker,Reinhold Vieth,Choong-Chin Liew,David M. Hwang,Jovan Evrovski,Geoffrey N. Hendy +8 more
TL;DR: The CASR A986S polymorphism is a likely candidate locus for genetic predisposition to various bone and mineral disorders in which extracellular calcium concentrations have a prominent part.
Journal ArticleDOI
A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee.
Andre L. Moreira,Paolo S. Ocampo,Yuhe Xia,Hua Zhong,Prudence A. Russell,Yuko Minami,Wendy A Cooper,Akihiko Yoshida,Lukas Bubendorf,Mauro Papotti,Giuseppe Pelosi,Fernando Lopez-Rios,Keiko Kunitoki,Dana Ferrari-Light,Lynette M. Sholl,Mary Beth Beasley,Alain C. Borczuk,Johan Botling,Elisabeth Brambilla,Gang Chen,Teh Ying Chou,Jin Haeng Chung,Sanja Dacic,Deepali Jain,Fred R. Hirsch,David M. Hwang,Sylvie Lantuejoul,Dongmei Lin,John W. Longshore,Noriko Motoi,Masayuki Noguchi,Claudia Poleri,Natasha Rekhtman,Ming-Sound Tsao,Erik Thunnissen,William D. Travis,Yasushi Yatabe,Anja C. Roden,Jillian B. Daigneault,Ignacio I. Wistuba,Keith M. Kerr,Harvey I. Pass,Andrew G. Nicholson,Mari Mino-Kenudson +43 more
TL;DR: A grading system based on the predominant and high-grade patterns is practical and prognostic for invasive pulmonary adenocarcinoma.
Journal ArticleDOI
Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer
Charles Henry Lim,Ming-Sound Tsao,Lisa W. Le,Frances A. Shepherd,Ronald Feld,Ronald Burkes,Geoffrey Liu,Suzanne Kamel-Reid,David M. Hwang,Jeffrey Tanguay,G. da Cunha Santos,Natasha B. Leighl +11 more
TL;DR: Awaiting biomarker testing results can delay treatment decisions and treatment initiation for patients with advanced NSCLC, and this may be avoided by incorporating reflex biomarkerTesting into diagnostic algorithms forNSCLC at the level of the pathologist, and further education of specialists involved in obtaining diagnostic cancer specimens to ensure they are sufficient for molecular testing.
Journal ArticleDOI
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Lynette M. Sholl,Fred R. Hirsch,David M. Hwang,Johan Botling,Fernando López-Ríos,Lukas Bubendorf,Mari Mino-Kenudson,Anja C. Roden,Mary Beth Beasley,Alain C. Borczuk,Elisabeth Brambilla,Gang Chen,Teh Ying Chou,Jin Haeng Chung,Wendy A Cooper,Sanja Dacic,Sylvie Lantuejoul,Deepali Jain,Dongmei Lin,Yuko Minami,Andre L. Moreira,Andrew G. Nicholson,Masayuki Noguchi,Mauro Papotti,Giuseppe Pelosi,Claudia Poleri,Natasha Rekhtman,Ming-Sound Tsao,Erik Thunnissen,William D. Travis,Yasushi Yatabe,Akihiko Yoshida,Jillian B. Daigneault,Ahmet Zehir,Solange Peters,Ignacio I. Wistuba,Keith M. Kerr,John W. Longshore +37 more
TL;DR: Effective prediction of response to ICI therapy will likely require integration of TMB with a host of other potential biomarkers, including tumor genomic driver alterations, tumor-immune milieu, and other features of the host immune system.